BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28864536)

  • 21. BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea.
    Kim M; Jeon MJ; Oh HS; Park S; Kim TY; Shong YK; Kim WB; Kim K; Kim WG; Song DE
    Thyroid; 2018 Apr; 28(4):504-510. PubMed ID: 29439609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma.
    Penna GC; Pestana A; Cameselle JM; Momesso D; de Andrade FA; Vidal APA; Araujo Junior ML; Melo M; Fernandes PV; Corbo R; Vaisman M; Sobrinho-Simões M; Soares P; Vaisman F
    Endocrine; 2018 Sep; 61(3):489-498. PubMed ID: 29948935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers.
    Gupta N; Dasyam AK; Carty SE; Nikiforova MN; Ohori NP; Armstrong M; Yip L; LeBeau SO; McCoy KL; Coyne C; Stang MT; Johnson J; Ferris RL; Seethala R; Nikiforov YE; Hodak SP
    J Clin Endocrinol Metab; 2013 May; 98(5):E914-22. PubMed ID: 23539734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics.
    Xu B; Tuttle RM; Sabra MM; Ganly I; Ghossein R
    Thyroid; 2017 May; 27(5):632-640. PubMed ID: 28049366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer.
    Jin A; Xu J; Wang Y
    Medicine (Baltimore); 2018 Jul; 97(29):e11548. PubMed ID: 30024548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TERT Promoter Mutations in Thyroid Cancer.
    Alzahrani AS; Alsaadi R; Murugan AK; Sadiq BB
    Horm Cancer; 2016 Jun; 7(3):165-77. PubMed ID: 26902827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TERT, HRAS, and EIF1AX Mutations in a Patient with Follicular Adenoma.
    Topf MC; Wang ZX; Tuluc M; Pribitkin EA
    Thyroid; 2018 Jun; 28(6):815-817. PubMed ID: 29669480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Ultrasonography Features of Follicular Thyroid Carcinoma With Tumor Invasiveness and Prognosis Based on WHO Classification and TERT Promoter Mutation.
    Kim MK; Park H; Oh YL; Shin JH; Kim TH; Hahn SY
    Korean J Radiol; 2024 Jan; 25(1):103-112. PubMed ID: 38184773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ectopic Thyroid Tissue: Immunohistochemistry and Molecular Analysis.
    Lin DM; Javidiparsijani S; Vardouniotis A; Buckingham L; Reddy SB; Gattuso P
    Appl Immunohistochem Mol Morphol; 2018; 26(10):734-739. PubMed ID: 28362711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population.
    Argyropoulou M; Veskoukis AS; Karanatsiou PM; Manolakelli A; Kostoglou-Athanassiou I; Vilaras G; Karameris A; Liadaki K
    Pathol Oncol Res; 2020 Jan; 26(1):347-354. PubMed ID: 30361901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
    Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
    JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysis.
    Liu C; Liu Z; Chen T; Zeng W; Guo Y; Huang T
    Sci Rep; 2016 Nov; 6():36990. PubMed ID: 27833153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low frequency of TERT promoter mutations in a series of well-differentiated follicular-patterned thyroid neoplasms.
    Proietti A; Sartori C; Macerola E; Borrelli N; Materazzi G; Vitti P; Basolo F
    Virchows Arch; 2017 Dec; 471(6):769-773. PubMed ID: 28975450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
    Witt RL
    Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort.
    Fukahori M; Yoshida A; Hayashi H; Yoshihara M; Matsukuma S; Sakuma Y; Koizume S; Okamoto N; Kondo T; Masuda M; Miyagi Y
    Thyroid; 2012 Jul; 22(7):683-9. PubMed ID: 22650231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Testing for Oncogenic Gene Alterations in Pediatric Thyroid Lesions.
    Mostoufi-Moab S; Labourier E; Sullivan L; LiVolsi V; Li Y; Xiao R; Beaudenon-Huibregtse S; Kazahaya K; Adzick NS; Baloch Z; Bauer AJ
    Thyroid; 2018 Jan; 28(1):60-67. PubMed ID: 29108474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and molecular features of Hürthle cell carcinoma of the thyroid.
    Chindris AM; Casler JD; Bernet VJ; Rivera M; Thomas C; Kachergus JM; Necela BM; Hay ID; Westphal SA; Grant CS; Thompson GB; Schlinkert RT; Thompson EA; Smallridge RC
    J Clin Endocrinol Metab; 2015 Jan; 100(1):55-62. PubMed ID: 25259908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.
    Bu R; Siraj AK; Divya SP; Kong Y; Parvathareddy SK; Al-Rasheed M; Al-Obaisi KAS; Victoria IG; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
    Int J Cancer; 2018 May; 142(10):2028-2039. PubMed ID: 29266240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TERT promoter mutations and long-term survival in patients with thyroid cancer.
    Kim TH; Kim YE; Ahn S; Kim JY; Ki CS; Oh YL; Kim K; Yun JW; Park WY; Choe JH; Kim JH; Kim JS; Kim SW; Chung JH
    Endocr Relat Cancer; 2016 Oct; 23(10):813-23. PubMed ID: 27528624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of estrogen receptor Beta expression in follicular thyroid carcinoma predicts poor outcome.
    Heikkilä A; Hagström J; Mäenpää H; Louhimo J; Siironen P; Heiskanen I; Haglund C; Arola J
    Thyroid; 2013 Apr; 23(4):456-65. PubMed ID: 23106428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.